MENU
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
  • About Us
  • Blog
  • Series
  • Category
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
  1. Home
  2. Mammography

Mammography– tag –

  • Reading Breast Cancer with AI

    What Multimodal AI Beating Oncotype DX Reveals: 3 Structural Shifts in HR+/HER2- Recurrence Decisions (C-index 0.733 vs 0.631) | Reading Breast Cancer Diagnosis with AI, Vol.3

    At SABCS 2025, multimodal AI (ICM+ model) outperforms Oncotype DX for 15-year recurrence prediction (C-index 0.733 vs 0.631). Final volume of our series.
    2026-04-29
  • Reading Breast Cancer with AI

    Reading the AITIC Trial: Where Partially Autonomous AI Triage Heads After a 63% Workload Cut and 14.8% Recall Rise | Reading Breast Cancer Diagnosis with AI, Vol.2

    Spain's AITIC trial (Nature Medicine 2026, n=31,301): partially autonomous AI workflow cuts radiologist workload 63.6%, lifts detection 15.2%. Vol. 2.
    2026-04-28
  • Reading Breast Cancer with AI

    What MASAI Reveals: 12% Fewer Interval Cancers and 4 Tensions Reshaping AI Mammography | Reading Breast Cancer Diagnosis with AI, Vol.1

    Sweden's MASAI trial (Lancet 2026, n>105,000) shows AI mammography cuts interval cancers by 12% and lifts sensitivity to 80.5%. Vol. 1 of our series.
    2026-04-26
1
MorningMorning|管理人

創薬の最前線に20年以上。基礎研究から新薬開発、そして投資の側まで――投資家の視点も持ちながら、がん領域を軸に日米欧で歩いてきました。最先端のがん治療・創薬・AI創薬・バイオ投資を、正確に、面白く、毎日お届けします。

▶ もっと詳しく(プロフィール)

▶ X:@MorningGlorySci

コメント・ご質問、お待ちしています。

MorningMorning|Author

20+ years at the frontline of drug discovery — from basic research to development to the investor's side. Oncology-focused, across Japan, the US, and Europe. Cutting-edge cancer therapy, drug discovery, AI drug development, and biotech investment — accurate and engaging, every day.

▶ More (Profile)

▶ X: @MorningGlorySci

Comments & questions welcome.

  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語

© Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~.

  • Menu
  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語